Objective: The aim of this study was to investigate the effect of Lipoprotein-a [Lp(a)] on Coronary Revascularizaton (CR) on one year follow up in patients with Acute Coronary Syndrome (ACS) after the first Percutaneo...Objective: The aim of this study was to investigate the effect of Lipoprotein-a [Lp(a)] on Coronary Revascularizaton (CR) on one year follow up in patients with Acute Coronary Syndrome (ACS) after the first Percutaneous Coronary Intervention (PCI). Method: A retrospective study was designed. A total of 475 patients that underwent their first PCI treatment due to ACS between January 2016 and December 2017 were recruited and followed for one year at the Zhongda Hospital, China. The clinical end point after first PCI was prevalence of Major Adverse Cardiovascular Events (MACE) including nonfatal Myocardial Infarction (MI), cardiovascular death, ischemic stroke and Coronary Revascularization (CR). According to the cut point of Lp(a), participants were divided into low Lp(a) subgroup (Lp(a) mg/L) and high Lp(a) subgroup (Lp(a) ≥ 300 mg/L). Furthermore, based on baseline Low Density Lipoprotein Cholesterol (LDL-C) level, participants were divided into low LDL-C (LDL-C mmol/L) and high LDL-C (LDL-C ≥ 1.8 mmol/L) subgroups. Results: The number of prevalence of CR was higher with elevated serum Lp(a) in both low LDL-C subgroup and high LDL-C subgroup, and was significantly different in both the low LDL-C subgroup and high LDL-C subgroup (p = 0.009 and p = 0.006, respectively). Multivariate Cox-hazard regression analysis for CR showed increase in serum LDL-C and Lp(a) increased prevalence of CR by 1.514 and 1.002 folds respectively. Furthermore, Kaplan-Meier cumulative survival curves showed that increased prevalence of CR within one year after first PCI in patients with high Lp(a) [log rank p = 0.000]. Conclusion: Baseline increase of serum LDL-C and Lp(a) significantly increases the prevalence of CR after first PCI within one year. It indicates that after PCI treatment, in patient with serum LDL-C and Lp(a) elevation, treatment with high-dose statin therapy or PCSK9 inhibitors may alleviate the adverse effects imposed by Lp(a) elevation.展开更多
Objective This study aimed to investigate the expression and clinical significance of serum lipoprotein(a) [LP(a)] in patients with gastric cancer. Methods Two hundred and twenty-two patients with gastric cancer(gastr...Objective This study aimed to investigate the expression and clinical significance of serum lipoprotein(a) [LP(a)] in patients with gastric cancer. Methods Two hundred and twenty-two patients with gastric cancer(gastric cancer group) were selected from 2015 to 2017 [mean age(58.40 ± 10.40) years], as were 101 healthy persons [normal age group, mean age(58.18 ± 11.42) years]. Fasting blood samples were collected and evaluated by immunoturbidimetry with a biochemical analyzer. LP(a) concentration was observed and its difference was compared. Results There was no significant correlation between LP(a) and tumor stage(P > 0.05). Compared with the control group, the level of LP(a) in the male gastric cancer group was significantly higher than that in the control group(P < 0.05). In the subgroup analysis, the level of LP(a) and abnormal rate showed an increasing trend among patients with stages I–IV gastric cancer. The level of LP(a) in poorly differentiated gastric cancer patients was higher than that in the high middle differentiation group(P < 0.05). There was no significant difference in LP(a) levels among patients with different pathological types of gastric cancer(P > 0.05). Conclusion LP(a) was correlated with the occurrence, development and differentiation of gastric cancer, but not with the pathological classification of gastric cancer. Serum LP(a) concentration may be used as an indicator for the staging and prognosis of gastric cancer, but the specific underlying mechanism remains to be further studied.展开更多
文摘Objective: The aim of this study was to investigate the effect of Lipoprotein-a [Lp(a)] on Coronary Revascularizaton (CR) on one year follow up in patients with Acute Coronary Syndrome (ACS) after the first Percutaneous Coronary Intervention (PCI). Method: A retrospective study was designed. A total of 475 patients that underwent their first PCI treatment due to ACS between January 2016 and December 2017 were recruited and followed for one year at the Zhongda Hospital, China. The clinical end point after first PCI was prevalence of Major Adverse Cardiovascular Events (MACE) including nonfatal Myocardial Infarction (MI), cardiovascular death, ischemic stroke and Coronary Revascularization (CR). According to the cut point of Lp(a), participants were divided into low Lp(a) subgroup (Lp(a) mg/L) and high Lp(a) subgroup (Lp(a) ≥ 300 mg/L). Furthermore, based on baseline Low Density Lipoprotein Cholesterol (LDL-C) level, participants were divided into low LDL-C (LDL-C mmol/L) and high LDL-C (LDL-C ≥ 1.8 mmol/L) subgroups. Results: The number of prevalence of CR was higher with elevated serum Lp(a) in both low LDL-C subgroup and high LDL-C subgroup, and was significantly different in both the low LDL-C subgroup and high LDL-C subgroup (p = 0.009 and p = 0.006, respectively). Multivariate Cox-hazard regression analysis for CR showed increase in serum LDL-C and Lp(a) increased prevalence of CR by 1.514 and 1.002 folds respectively. Furthermore, Kaplan-Meier cumulative survival curves showed that increased prevalence of CR within one year after first PCI in patients with high Lp(a) [log rank p = 0.000]. Conclusion: Baseline increase of serum LDL-C and Lp(a) significantly increases the prevalence of CR after first PCI within one year. It indicates that after PCI treatment, in patient with serum LDL-C and Lp(a) elevation, treatment with high-dose statin therapy or PCSK9 inhibitors may alleviate the adverse effects imposed by Lp(a) elevation.
文摘Objective This study aimed to investigate the expression and clinical significance of serum lipoprotein(a) [LP(a)] in patients with gastric cancer. Methods Two hundred and twenty-two patients with gastric cancer(gastric cancer group) were selected from 2015 to 2017 [mean age(58.40 ± 10.40) years], as were 101 healthy persons [normal age group, mean age(58.18 ± 11.42) years]. Fasting blood samples were collected and evaluated by immunoturbidimetry with a biochemical analyzer. LP(a) concentration was observed and its difference was compared. Results There was no significant correlation between LP(a) and tumor stage(P > 0.05). Compared with the control group, the level of LP(a) in the male gastric cancer group was significantly higher than that in the control group(P < 0.05). In the subgroup analysis, the level of LP(a) and abnormal rate showed an increasing trend among patients with stages I–IV gastric cancer. The level of LP(a) in poorly differentiated gastric cancer patients was higher than that in the high middle differentiation group(P < 0.05). There was no significant difference in LP(a) levels among patients with different pathological types of gastric cancer(P > 0.05). Conclusion LP(a) was correlated with the occurrence, development and differentiation of gastric cancer, but not with the pathological classification of gastric cancer. Serum LP(a) concentration may be used as an indicator for the staging and prognosis of gastric cancer, but the specific underlying mechanism remains to be further studied.
